IL-5 Inhibitors Prior Authorization with Quantity Limit Program Summary
Customize your policy alerts
Sign up for all prime_therapeutics policy alerts
Know when prime_therapeutics releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization, renewal, and quantity-limit approval for Fasenra (benralizumab) and Nucala (mepolizumab) for covered eosinophilic and related inflammatory conditions. It applies to Boeing commercial members and requires clinical documentation, condition-specific maintenance therapy, specialist involvement, and review of concomitant immunomodulator use.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.